These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34415167)

  • 1. Interrogating the Inhibition Mechanisms of Human Aldehyde Oxidase by X-ray Crystallography and NMR Spectroscopy: The Raloxifene Case.
    Mota C; Diniz A; Coelho C; Santos-Silva T; Esmaeeli M; Leimkühler S; Cabrita EJ; Marcelo F; Romão MJ
    J Med Chem; 2021 Sep; 64(17):13025-13037. PubMed ID: 34415167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent inhibition of human liver aldehyde oxidase by raloxifene.
    Obach RS
    Drug Metab Dispos; 2004 Jan; 32(1):89-97. PubMed ID: 14709625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of xanthine oxidase by the aldehyde oxidase inhibitor raloxifene: implications for identifying molybdopterin nitrite reductases.
    Weidert ER; Schoenborn SO; Cantu-Medellin N; Choughule KV; Jones JP; Kelley EE
    Nitric Oxide; 2014 Feb; 37():41-5. PubMed ID: 24406683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human aldehyde oxidase (hAOX1): structure determination of the Moco-free form of the natural variant G1269R and biophysical studies of single nucleotide polymorphisms.
    Mota C; Esmaeeli M; Coelho C; Santos-Silva T; Wolff M; Foti A; Leimkühler S; Romão MJ
    FEBS Open Bio; 2019 May; 9(5):925-934. PubMed ID: 30985987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights about the monomer and homodimer structures of the human AOX1.
    Ferreira P; Cerqueira NMFSA; Coelho C; Fernandes PA; Romão MJ; Ramos MJ
    Phys Chem Chem Phys; 2019 Jul; 21(25):13545-13554. PubMed ID: 31172995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro and In Silico Analyses of the Inhibition of Human Aldehyde Oxidase by Bazedoxifene, Lasofoxifene, and Structural Analogues.
    Chen S; Austin-Muttitt K; Zhang LH; Mullins JGL; Lau AJ
    J Pharmacol Exp Ther; 2019 Oct; 371(1):75-86. PubMed ID: 31289113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation.
    Chen Q; Ngui JS; Doss GA; Wang RW; Cai X; DiNinno FP; Blizzard TA; Hammond ML; Stearns RA; Evans DC; Baillie TA; Tang W
    Chem Res Toxicol; 2002 Jul; 15(7):907-14. PubMed ID: 12119000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase.
    Coelho C; Foti A; Hartmann T; Santos-Silva T; Leimkühler S; Romão MJ
    Nat Chem Biol; 2015 Oct; 11(10):779-83. PubMed ID: 26322824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of Zaleplon 5-Oxidase Activity in Mice and Humans, and Inhibition by Raloxifene.
    Tanoue C; Sugihara K; Tayama Y; Uramaru N; Watanabe Y; Ohta S; Kitamura S
    Drug Metab Lett; 2017; 10(4):278-285. PubMed ID: 28029084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human liver aldehyde oxidase: inhibition by 239 drugs.
    Obach RS; Huynh P; Allen MC; Beedham C
    J Clin Pharmacol; 2004 Jan; 44(1):7-19. PubMed ID: 14681337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of 4D-QSAR studies to a series of raloxifene analogs and design of potential selective estrogen receptor modulators.
    Sodero AC; Romeiro NC; da Cunha EF; de Oliveira Magalhaães U; de Alencastro RB; Rodrigues CR; Cabral LM; Castro HC; Albuquerque MG
    Molecules; 2012 Jun; 17(6):7415-39. PubMed ID: 22706372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of raloxifene hydrochloride.
    Saitta A; Morabito N; Frisina N; Cucinotte D; Corrado F; D'Anna R; Altavilla D; Squadrito G; Minutoli L; Arcoraci V; Cancellieri F; Squadrito F
    Cardiovasc Drug Rev; 2001; 19(1):57-74. PubMed ID: 11314601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5.
    Morrison RD; Blobaum AL; Byers FW; Santomango TS; Bridges TM; Stec D; Brewer KA; Sanchez-Ponce R; Corlew MM; Rush R; Felts AS; Manka J; Bates BS; Venable DF; Rodriguez AL; Jones CK; Niswender CM; Conn PJ; Lindsley CW; Emmitte KA; Daniels JS
    Drug Metab Dispos; 2012 Sep; 40(9):1834-45. PubMed ID: 22711749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach.
    Adusumalli S; Jamwal R; Obach RS; Ryder TF; Leggio L; Akhlaghi F
    Drug Metab Dispos; 2019 Aug; 47(8):874-882. PubMed ID: 31182423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
    Barr JT; Jones JP
    Drug Metab Dispos; 2013 Jan; 41(1):24-9. PubMed ID: 22996261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene.
    Seeman E
    J Bone Miner Metab; 2001; 19(2):65-75. PubMed ID: 11281162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
    Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
    ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
    Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
    J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldehyde Oxidase Contributes to All-
    Zhong G; Seaman CJ; Paragas EM; Xi H; Herpoldt KL; King NP; Jones JP; Isoherranen N
    Drug Metab Dispos; 2021 Mar; 49(3):202-211. PubMed ID: 33355213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raloxifene increases prefrontal activity during emotional inhibition in schizophrenia based on estrogen receptor genotype.
    Kindler J; Weickert CS; Schofield PR; Lenroot R; Weickert TW
    Eur Neuropsychopharmacol; 2016 Dec; 26(12):1930-1940. PubMed ID: 27842943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.